All In Biotech

Drug Trial Radar · NCT00730197

Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets 40 mg

Single-Dose Fasting Bioequivalence Study of Nisoldipine Extended-Release Tablets(40 mg; Mylan) and Sular® Extended Release Tablets (40 mg; First Horizon) in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Aug 8, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Feb 2007

Primary completion

Mar 2007

Study completion Mar 2007

Sponsor

Lead sponsor
Mylan Pharmaceuticals IncIndustry
Sponsor type
Industry
First posted
Aug 8, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study was to investigate the bioequivalence of nisoldipine extended-release 40 mg tablets (by Mylan Pharmaceuticals Inc.) with Sular® Extended-Release 40 mg tablet (manufactured for First Horizon) following a single, oral 40 mg (1 × 40 mg tablet) dose administration in healthy adult subjects under fasting conditions.

Conditions

  • Healthy

Interventions

  • Albuterol Sulfate Extended-Release Tablets 8 mgDrug

    8mg, single dose fed

  • VoSpire® ER Tablets 8 mgDrug

    8mg, single dose fed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BioequivalenceTime frame: within 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PRACS Institute, Ltd.

    Fargo, North Dakota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.